Literature DB >> 18849502

Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases.

Wolfgang Luboldt1, Rainer Küfer, Norbert Blumstein, Todd L Toussaint, Alexander Kluge, Marcus D Seemann, Hans-Joachim Luboldt.   

Abstract

In a technical development study approved by the institutional ethics committee, the feasibility of fast diffusion-weighted imaging as a replacement for conventional magnetic resonance (MR) imaging sequences (short inversion time inversion recovery [STIR] and T1-weighted spin echo [SE]) and positron emission tomography (PET)/computed tomography (CT) in the detection of skeletal metastases from prostate cancer was evaluated. MR imaging and carbon 11 ((11)C) choline PET/CT data from 11 consecutive prostate cancer patients with bone metastases were analyzed. Diffusion-weighted imaging appears to be equal, if not superior, to STIR and T1-weighted SE sequences and equally as effective as (11)C-choline PET/CT in detection of bone metastases in these patients. Diffusion-weighted imaging should be considered for further evaluation and comparisons with PET/CT for comprehensive whole-body staging and restaging in prostate and other cancers. RSNA, 2008

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849502     DOI: 10.1148/radiol.2492080038

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  27 in total

1.  C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.

Authors:  Evan Y Yu; Mark Muzi; Joy A Hackenbracht; Brian B Rezvani; Jeanne M Link; Robert Bruce Montgomery; Celestia S Higano; Janet F Eary; David A Mankoff
Journal:  Clin Nucl Med       Date:  2011-03       Impact factor: 7.794

Review 2.  PET/MR in prostate cancer: technical aspects and potential diagnostic value.

Authors:  Michael Souvatzoglou; Matthias Eiber; Axel Martinez-Moeller; Sebastian Fürst; Konstantin Holzapfel; Tobias Maurer; Sibylle Ziegler; Stephan Nekolla; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-24       Impact factor: 9.236

3.  Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility.

Authors:  C Messiou; D J Collins; V A Morgan; N M Desouza
Journal:  Eur Radiol       Date:  2011-04-07       Impact factor: 5.315

Review 4.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 5.  Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective.

Authors:  Antonis Kalemis; Bénédicte M A Delattre; Susanne Heinzer
Journal:  MAGMA       Date:  2012-08-07       Impact factor: 2.310

6.  Role of whole-body diffusion-weighted MRI in detecting bone metastasis.

Authors:  Riccardo Del Vescovo; Giulia Frauenfelder; Francesco Giurazza; Claudia Lucia Piccolo; Roberto Luigi Cazzato; Rosario Francesco Grasso; Emiliano Schena; Bruno Beomonte Zobel
Journal:  Radiol Med       Date:  2014-03-18       Impact factor: 3.469

Review 7.  Imaging and evaluation of patients with high-risk prostate cancer.

Authors:  Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

8.  Deep MR Brain Image Super-Resolution Using Spatio-Structural Priors.

Authors:  Venkateswararao Cherukuri; Tiantong Guo; Steven J Schiff; Vishal Monga
Journal:  IEEE Trans Image Process       Date:  2019-09-25       Impact factor: 10.856

Review 9.  Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.

Authors:  Laura Evangelista; Francesco Bertoldo; Francesco Boccardo; Giario Conti; Ilario Menchi; Francesco Mungai; Umberto Ricardi; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-09       Impact factor: 9.236

Review 10.  Imaging metastatic bone disease from carcinoma of the prostate.

Authors:  C Messiou; G Cook; N M deSouza
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.